Also trades as: CMND.CN (CNQ) · $vol 0M
CMND NASDAQ
Clearmind Medicine Inc.
1W: -13.4%
1M: -34.9%
3M: +99.5%
YTD: -18.6%
1Y: -96.1%
3Y: -99.7%
$1.46
-0.16 (-9.88%)
Weekly Expected Move ±10.3%
$1
$1
$2
$2
$2
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.2M
52W Range1.43-524
Volume324,945
Avg Volume2,038,113
Beta-1.19
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOAdi Zuloff-Shani
Employees4
SectorHealthcare
IndustryBiotechnology
IPO Date2022-11-15
Websiteclearmindmedicine.com
1220 West 6th Avenue
Vancouver, BC V6H 1A5
CA
Vancouver, BC V6H 1A5
CA
604 260 1566
About Clearmind Medicine Inc.
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions. The company's research targets conditions such as alcohol use disorder (including problematic binge drinking), various eating disorders (like binge eating), depression, and other compulsive or "binge" behaviors. Founded in 2017, the company initially operated under the name Cyntar Ventures Inc. before officially rebranding as Clearmind Medicine Inc. in March 2021. Its operations are headquartered in Vancouver, Canada.
Latest News
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial
Clearmind Medicine Expends Global IP portfolio with Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‑Billion‑Dollar PTSD Therapeutics Market
Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| HRT FINANCIAL LP | S-Sale | 22,139 | $3.31 | 2026-06-16 |
| HRT FINANCIAL LP | S-Sale | 3,183 | $3.32 | 2026-06-15 |
| HRT FINANCIAL LP | S-Sale | 2,102 | $3.36 | 2026-06-12 |
| HRT FINANCIAL LP | 0 | — | 2026-06-10 | |
| Lamadrid David | A-Award | 857,143 | $0.35 | 2017-05-12 |